Classification
Compound class	Synthetic organic
Approved drug?	Yes (FDA (2017))

IUPAC Name

4-[8-amino-3-[(2S)-1-but-2-ynoylpyrrolidin-2-yl]imidazo[1,5-a]pyrazin-1-yl]-N-pyridin-2-ylbenzamide

International Nonproprietary Names
INN number	INN
10150	acalabrutinib

Synonyms

ACP-196 | Calquence® | Example 6 [US20140155385 A1] [1]

Database Links
CAS Registry No.	1420477-60-6 (source: INN record)
GtoPdb PubChem SID	310264693
PubChem CID	71226662
Search Google for chemical match using the InChIKey	WDENQIQQYWYTPO-IBGZPJMESA-N
Search Google for chemicals with the same backbone	WDENQIQQYWYTPO
Search PubMed clinical trials	acalabrutinib
Search PubMed titles	acalabrutinib
Search PubMed titles/abstracts	acalabrutinib
Search UniChem for chemical match using the InChIKey	WDENQIQQYWYTPO-IBGZPJMESA-N
Search UniChem for chemicals with the same backbone	WDENQIQQYWYTPO

Comments

Acalabrutinib is an orally available second-generation, selective and irreversible inhibitor of Bruton tyrosine kinase (BTK) [3], being investigated for its potential antineoplastic activity (in multiple haematologic malignancies and solid tumours), as well as a potential therapy for rheumatoid arthritis. Acalabrutinib covalently bonds to Cysteine-481 in BTK.